U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30Cl2N2O5
Molecular Weight 461.379
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXLOXIGLUMIDE

SMILES

CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1

InChI

InChIKey=QNQZBKQEIFTHFZ-GOSISDBHSA-N
InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H30Cl2N2O5
Molecular Weight 461.379
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Dexloxiglumide is a selective antagonist of cholecystokinin receptor A (CCKA, CCK1). It is the dextro isomeric form of loxiglumide, Dexloxiglumide was investigated for treatment of irritable bowel syndrome. Its development in USA was discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P32238
Gene ID: 886.0
Gene Symbol: CCKAR
Target Organism: Homo sapiens (Human)
7.53 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder.
2001 Dec
Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.
2004 May
The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender.
2005 Sep
Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients.
2006 Aug
A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat.
2006 Jul-Aug
Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion.
2010 Feb
Patents

Sample Use Guides

In phase 2 clinical trials for treatment of constipation predominant irritable bowel syndrome dexloxiglumide was administered at doses 200 mg tid.
Route of Administration: Oral
Binding of dexloxiglumide to cholecystokinin receptor 1 (CCK1) was studied using radioligand binding assay. CHO cells were transfected with CCK1. Cell membanes rere incubated with 60 pM 125I-BH-CCK-8S (Bolton Hunter-sulfated cholecystokinin octapeptide), and treated with varying concentration of dexloxiglumide. The bound radioactivity was separated by filtration, and radioactivity retained on the filters was measured by liquid scintillation counting.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:27:01 GMT 2023
Edited
by admin
on Sat Dec 16 16:27:01 GMT 2023
Record UNII
69DY40RH9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXLOXIGLUMIDE
INN   WHO-DD  
INN  
Official Name English
LOXIGLUMIDE (R)-FORM
MI  
Common Name English
LOXIGLUMIDE (R)-FORM [MI]
Common Name English
CR-2017
Code English
(+)-LOXIGLUMIDE
Common Name English
LOXIGLUMIDE, (R)-
Common Name English
dexloxiglumide [INN]
Common Name English
(R)-4-(3,4-DICHLOROBENZAMIDO)-N-(3-METHOXYPROPYL)-N-PENTYLGLUTARAMIC ACID
Systematic Name English
Dexloxiglumide [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29701
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
NCI_THESAURUS C28197
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C96871
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
MESH
C103490
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
WIKIPEDIA
DEXLOXIGLUMIDE
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
DRUG BANK
DB04856
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
MERCK INDEX
m6916
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY Merck Index
CAS
119817-90-2
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
EVMPD
SUB07036MIG
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL550781
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
PUBCHEM
65937
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
SMS_ID
100000083408
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
INN
6782
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
FDA UNII
69DY40RH9B
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID50152604
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
DRUG CENTRAL
834
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
RACEMATE -> ENANTIOMER
Related Record Type Details
ACTIVE MOIETY